Source: ERJ Open Res, 3 (4) 00097-2017; 10.1183/23120541.00097-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Kondwani C. Jambo, Dumizulu L. Tembo, Arox W. Kamng'ona, Patrick Musicha, Dominic H. Banda, Anstead M. Kankwatira, Rose D. Malamba, Theresa J. Allain, Robert S. Heyderman, David G. Russell, Henry C. Mwandumba. HIV-associated disruption of lung cytokine networks is incompletely restored in asymptomatic HIV-infected Malawian adults on antiretroviral therapy. ERJ Open Res, 3 (4) 00097-2017; 10.1183/23120541.00097-2017

Member's Comments

No comment yet.

Related content which might interest you: Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006 Unmasking tuberculosis in the era of antiretroviral treatment Source: Eur Respir J 2012; 39: 1064-1075 Year: 2012 Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with advanced HIV disease Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004 TB infection in children receiving genetically engineered biologic drugs Source: International Congress 2019 – Paediatric tuberculosis Year: 2019 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Revealing and prophylaxis of a tuberculosis at HIV-infected persons Source: Eur Respir J 2006; 28: Suppl. 50, 22s Year: 2006 Quality of sleep and psychiatric parameters in patients with HIV infection on highly active antiretroviral therapy (HAART) Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Source: Eur Respir J 2005; 25: 751-757 Year: 2005 Efficacy of isoniazid preventive therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders-a retrospective cohort study in Taiwan Source: International Congress 2017 – Migrants and screening Year: 2017 Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy Source: Eur Respir J 2009; 34: 277-278 Year: 2009 Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen Source: Eur Respir J 2003; 21: 785-788 Year: 2003 Safety of the endobronchial valve use in the complex treatment of patients with destructive MDR/XDR TB associated with HIV infection. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Small airway dysfunction in well-treated never-smoking HIV-infected individuals Source: Eur Respir J , 49 (3) 1602186; DOI: 10.1183/13993003.02186-2016 Year: 2017 Impaired Mtb-specific alveolar T-cell responses in HIV+ persons with latent TB infection Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008 TB in children Source: Eur Respir Mon 2012; 58: 206-218 Year: 2012 Monitoring T-cell immunity towards M. tuberculosis: impaired specific immunocompetence in patients receiving high levels of immunosuppressive drugs Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008